A Phase 2, Open-label Trial Evaluating the Safety, Tolerability and Efficacy of ION775 in Adults With Hypertriglyceridemia
Status: Recruiting
Location: See all (16) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The main objective of this study is to evaluate the effect of ION775 on fasting triglyceride (TG) levels in participants with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (sHTG).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adult males and females with HTG (fasting TG more than or equal to (≥) 350 milligrams per deciliter (mg/dL) \[3.95 millimoles per liter (mmol/L)\] or with sHTG (fasting TG ≥ 500 mg/dL \[5.65 mmol/L\]).
• Participants should be on standard of care lipid-lowering medications per local guidelines.
Locations
United States
California
Ionis Investigative Site
RECRUITING
Lincoln
Colorado
Ionis Investigative Site
RECRUITING
Aurora
Florida
Ionis Investigative Site
RECRUITING
Boca Raton
Ionis Investigative Site
RECRUITING
Miami
Ionis Investigative Site
RECRUITING
Miramar
Georgia
Ionis Investigative Site
RECRUITING
Columbus
Kentucky
Ionis Investigative Site
RECRUITING
Louisville
Michigan
Ionis Investigative Site
RECRUITING
Flint
Ohio
Ionis Investigative Site
RECRUITING
Munroe Falls
South Carolina
Ionis Investigative Site
RECRUITING
Little River
Texas
Ionis Investigative Site
RECRUITING
Houston
Ionis Investigative Site
RECRUITING
Lampasas
Ionis Investigative Site
RECRUITING
Mckinney
Ionis Investigative Site
RECRUITING
Mesquite
Ionis Investigative Site
RECRUITING
San Antonio
Other Locations
Canada
Ionis Investigative Site
RECRUITING
Québec
Contact Information
Primary
Ionis Pharmaceuticals, Inc.
IonisION775-CS2@clinicaltrialmedia.com
1-844-828-3770
Time Frame
Start Date: 2026-05-12
Estimated Completion Date: 2028-03
Participants
Target number of participants: 72
Treatments
Experimental: ION775: Cohot A
Participants will be randomized to receive ION775 by subcutaneous (SC) injection.
Experimental: ION775: Cohot B
Participants will be randomized to receive ION775 by SC injection.
Experimental: ION775: Cohot C
Participants will be randomized to receive ION775 by SC injection.
Related Therapeutic Areas
Sponsors
Leads: Ionis Pharmaceuticals, Inc.